Nanyang Biologics
Nanyang Biologics announces $1.5B business combination with RF Acquisition Corp II to pursue Nasdaq listing
Nanyang Biologics Pte. Ltd. (NYB), together with its subsidiaries, announced the signing of a business combination agreement with RF Acquisition Corp II, a publicly listed special purpose acquisition company, to pursue Nasdaq listing.
Nanyang Biologics, Equinix and HPE team up for AI drug discovery platform
Singapore artificial intelligence (AI) biotech firm Nanyang Biologics Pte Ltd (NYB) is teaming up with Equinix and HPE to offer Vecura, an as-a-Service proprietary AI-driven platform for drug discovery to advance development from natural sources.
